Pharma/Biotech News
Subscribe to Pharma/Biotech News

The Lead

The Story of Biogen's Alzheimer's Drug, Aducanumab

April 28, 2015 10:28 am | by Cynthia Fox, Science Writer | Articles | Comments

The Biogen anti-amyloid antibody, aducanumab, took the 12th International Conference on Alzheimer’s and Parkinson’s Diseases in Nice, France by storm last month. The drug seemed able to significantly reduce amyloid in patients’ brains, while demonstrably slowing cognitive degeneration. It had analysts and scientists alike buzzing. Read more...

Molecular Health Gains European Patent for Novel Receptor

April 28, 2015 8:54 am | News | Comments

It addresses unmet need in treatment of millions of cancer patients. Read more...

GSK Shingles Vaccine Demonstrates 97.2% Efficacy in Phase 3 Study

April 28, 2015 8:37 am | News | Comments

GlaxoSmithKline presented detailed data from a randomized phase 3 study of its investigational...

Ebola Scare May Inform U.S.'s Response to Bioterrorism

April 27, 2015 2:50 pm | by Seth Augenstein, Digital Reporter | Articles | Comments

Last year’s Ebola scare might provide a blueprint for a response to the unthinkable: a ...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Mylan Declines Teva's $40B Takeover Attempt

April 27, 2015 12:08 pm | by Ryan Bushey, Associate Editor | Articles | Comments

The executive chairman for Mylan wrote a letter to Teva citing a number of issues as to why this merger would be a bad idea. Read more...

Lilly's Cyramza Receives Fourth FDA Approval

April 27, 2015 12:07 pm | News | Comments

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration (FDA) approval for Cyramza (ramucirumab). Read more...

Allergan to Cut Hundreds of U.S. Jobs

April 27, 2015 9:50 am | by Ryan Bushey, Associate Editor | Articles | Comments

A total of 674 staff members have been let go from Allergan’s operations in California so far since 2014. Read more...


MedDay Reports Positive Phase 3 Results from MS Drug Study

April 27, 2015 8:37 am | News | Comments

The study demonstrated evidence of the efficacy and safety of MD1003, a highly-concentrated pharmaceutical-grade biotin administered at a dose of 300 mg per day in the treatment of primary and secondary progressive multiple sclerosis, a major area of unmet medical need. Read more....

Bristol-Myers Gets Positive EMA Opinion for Immunotherapy Drug, Opdivo

April 24, 2015 12:36 pm | by Stephanie Guzowski, Editor | Articles | Comments

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Bristol-Myers Squibb’s Opdivo today for the treatment of melanoma. Read more..

FDA Grants Priority Review for AbbVie's Hepatitis C Treatment

April 24, 2015 12:16 pm | News | Comments

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).  Read more...

J&J Hikes Quarterly Dividend by 7 Percent

April 24, 2015 12:06 pm | by Linda A. Johnson, AP Business Writer | News | Comments

Johnson & Johnson on Thursday said it's raising its quarterly dividend by 7 percent, marking its 53rd straight year of dividend increases. Read more...

Manchester Joins European Consortium to Develop Liquid Biopsies

April 24, 2015 8:47 am | by University of Manchester | News | Comments

An international project to validate blood-based biomarkers for cancer has added a new member. Read more...


FDA Grants Priority Review for Boehringer Ingelheim's Idarucizumab

April 23, 2015 2:06 pm | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for idarucizumab. Read more...

FDA Accepts Filing of Bayer's MS Treatment

April 23, 2015 2:03 pm | News | Comments

Bayer is pleased to announce today that the U.S. Food and Drug Administration (FDA) has accepted the filing for Bayer's supplemental Biologics License Application (sBLA) for Betaconnect (proposed name), another delivery option for Betaseron (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis. 

Abbvie Raises Outlook as Humira Again Delivers Earnings Beat

April 23, 2015 1:36 pm | by Matthew Perrone, AP Health Writer | News | Comments

Drugmaker AbbVie is raising its full-year earnings guidance after reporting better-than-expected first quarter adjusted results on continued growth of its blockbuster anti-inflammatory drug Humira. Read more...

Pipeline Advancements, Asset Acquisitions Fueled Mid-Cap Biotech R&D Spend in 2014

April 23, 2015 12:22 pm | by Adam Dion, GlobalData's Senior Industry Analyst | Articles | Comments

The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014. Read more...

Roche Sales Up 3 Percent Amid Demand for Breast Cancer Drugs

April 23, 2015 9:15 am | by The Associated Press | News | Comments

Breast cancer drugs such as Herceptin as well as new uses for multi-cancer drug Avastin helped Swiss pharmaceutical firm Roche grow sales by 3 percent during the first quarter. Read more...


Human Clinical Trials Planned for New Anti-Cancer Compound

April 23, 2015 8:55 am | by University of Auckland | News | Comments

Researchers developed a new anti-cancer compound that will advance to human phase two clinical trials. Read more...

Link Between Serotonin and Depression is a Myth, Says Psychiatrist

April 22, 2015 2:11 pm | by Stephanie Guzowski, Editor | News | Comments

The widely held belief that depression is caused by low levels of serotonin and that certain antidepressants raise the levels of this neurotransmitter, is a myth, according to a psychiatrist in an editorial article in The BMJ this week. Read more...

AACR 2015: Pembrolizumab Comes Out on Top for Melanoma, Lung Cancer

April 22, 2015 10:33 am | by Stephanie Guzowski, Editor | Articles | Comments

At the AACR Annual Meeting 2015, immunotherapies, called PD-1 inhibitors, were front and center stage, due to clinical trial results that led to U.S. Food and Drug Administration (FDA) approvals for treating melanoma and non-small cell lung cancer (NSCLC). Read more..

Regulatory and Clinical Factors Limiting U.S. Non-Vascular Stent Market Growth

April 22, 2015 9:43 am | by Priya Radhakrishnan, Director of Medical Devices, GlobalData | News | Comments

The future growth of the non-vascular stent market by 2021 will be slower in the US than almost every other major market, due in part to an increasingly difficult regulatory process and the medical device excise tax, but primarily as a result of clinical factors and unmet needs still to be addressed, said research and consulting firm GlobalData. Read more...

Takeda: Research Collaboration with Keio University School of Medicine, Niigata University

April 21, 2015 3:36 pm | News | Comments

This will focus on the search for and functional analysis of disease-related RNA-binding proteins. Read more...

GW Pharmaceuticals Initiates Second Phase 3 Trial for Epidiolex

April 21, 2015 3:15 pm | News | Comments

This drug is intended for the treatment of Dravet syndrome. Read more...

Lupin Launches Zaxine in Canada

April 21, 2015 3:08 pm | News | Comments

The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in Canada. Read more...

Trial Shows Benefit of 'BRCA-targeting' Drug in Prostate Cancer

April 21, 2015 3:00 pm | by Institute of Cancer Research | News | Comments

Men with prostate cancer benefit from treatment with the pioneering drug olaparib. Read more...

Teva Offers to Buy Mylan in $40.1B Cash and Stock Deal

April 21, 2015 2:49 pm | by Linda A. Johnson, AP Business Writer | News | Comments

Generic drug giant Teva formally offered to buy fellow drugmaker Mylan about $40.1 billion in cash and stock on Tuesday. Read more...

Pfizer: FDA Breakthrough Therapy Designation for Lung Cancer Drug

April 21, 2015 11:57 am | News | Comments

Pfizer Inc. announced today that Xalkori (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Read more...

Merck, Pfizer Initiate Phase 3 Avelumab Study

April 21, 2015 11:26 am | News | Comments

Merck and Pfizer today announced the initiation and first patient treated in the international Phase 3 study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab. Read more...

Mylan Skeptical of Rumored Teva Bid

April 21, 2015 8:42 am | by The Associated Press | News | Comments

Mylan said that it hasn't received an offer and described the idea that Teva might want to buy it as a rumor. Read more...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.